Abivax has raised $920m (€807m) in gross proceeds through a US public offering, only days after new obefazimod data helped calm investor concerns over the drug’s safety profile in ulcerative colitis.
https://european-biotechnology.com/wp-content/uploads/2026/07/wesley-tingey-ak5yDsh1kDQ-unsplash-scaled.jpg17072560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-02 09:33:252026-07-02 09:33:25Abivax cashes in on investor enthusiasm with €807m raise
Swedish biotech AlzeCure Pharma has licensed global rights to its NeuroRestore platform, including lead Alzheimer’s candidate ACD856, to Danish biotech QuantumCell ApS in a deal worth more than $2.2bn, excluding royalties.
Paris-based Ipsen has agreed to acquire Swiss biotech Memo Therapeutics AG in a deal worth more than €700m, adding the clinical-stage BK polyomavirus antibody potravitug to its rare-disease pipeline.
InflaRx is preparing for discussions with regulators in Europe over two drugs that could provide an alternative to patients treated with Amgen’s Tavneos (avacopan), which is set to be removed from the EU market for the rare blood vessel inflammation disease ANCA-associated vasculitis (AAV).
https://european-biotechnology.com/wp-content/uploads/2026/07/imagine-buddy-FDaCU3etvAc-unsplash-scaled.jpg19392560Richard Staines/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngRichard Staines2026-07-01 09:33:452026-07-01 09:33:45InflaRx seeks to fill void left by Amgen’s Tavneos in Europe
Genmab and AbbVie reported positive phase 3 results for epcoritamab in combination with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), demonstrating a significant improvement in progression-free survival (PFS) compared with R-GemOx.
Munich-based smartbax has secured additional financing to advance its lead antibiotic programme, building on a €4.7m pre-Series A first close announced in October 2025.
https://european-biotechnology.com/wp-content/uploads/2026/06/allison-saeng-8e8Stpw4Gr8-unsplash-scaled.jpg18292560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-06-30 15:08:352026-06-30 15:08:35smartbax extends pre-series A to €6.3 m for new antibiotic
Abivax has reported additional Phase III maintenance data for obefazimod in ulcerative colitis, giving the French biotech more efficacy and safety evidence to support its planned US regulatory filing later this year.
https://european-biotechnology.com/wp-content/uploads/2026/06/jakub-zerdzicki-yKnIbJV0RbY-unsplash-scaled.jpg14402560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-06-30 11:51:012026-06-30 11:51:01Abivax answers safety questions with new data
UK immunotherapy developer Scancell has confirmed talks to acquire Nasdaq-listed Neuphoria Therapeutics, in a move that could give the Oxford-based biotech a faster route to US public markets.
Vienna-based Epitome Therapeutics has launched with €4 million in total financing to advance a new epigenome-editing platform designed to precisely control gene expression.
Telum raises €18M to push phage-derived antimicrobials toward clinic
Latest NewsSpanish biotech Telum Therapeutics has raised €18 million in Series A financing to move its lead antimicrobial programme toward clinical development.
Abivax cashes in on investor enthusiasm with €807m raise
Latest NewsAbivax has raised $920m (€807m) in gross proceeds through a US public offering, only days after new obefazimod data helped calm investor concerns over the drug’s safety profile in ulcerative colitis.
AlzeCure licenses Alzheimer’s asset to QuantumCell in $2.2bn deal
Latest NewsSwedish biotech AlzeCure Pharma has licensed global rights to its NeuroRestore platform, including lead Alzheimer’s candidate ACD856, to Danish biotech QuantumCell ApS in a deal worth more than $2.2bn, excluding royalties.
Ipsen’s buying streak continues with €700m Memo deal
Latest NewsParis-based Ipsen has agreed to acquire Swiss biotech Memo Therapeutics AG in a deal worth more than €700m, adding the clinical-stage BK polyomavirus antibody potravitug to its rare-disease pipeline.
InflaRx seeks to fill void left by Amgen’s Tavneos in Europe
Latest NewsInflaRx is preparing for discussions with regulators in Europe over two drugs that could provide an alternative to patients treated with Amgen’s Tavneos (avacopan), which is set to be removed from the EU market for the rare blood vessel inflammation disease ANCA-associated vasculitis (AAV).
Genmab shares rise following positive epcoritamab phase 3 data
Latest NewsGenmab and AbbVie reported positive phase 3 results for epcoritamab in combination with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), demonstrating a significant improvement in progression-free survival (PFS) compared with R-GemOx.
smartbax extends pre-series A to €6.3 m for new antibiotic
Latest NewsMunich-based smartbax has secured additional financing to advance its lead antibiotic programme, building on a €4.7m pre-Series A first close announced in October 2025.
Abivax answers safety questions with new data
Latest NewsAbivax has reported additional Phase III maintenance data for obefazimod in ulcerative colitis, giving the French biotech more efficacy and safety evidence to support its planned US regulatory filing later this year.
Scancell plots reverse-merger path to Nasdaq
Latest NewsUK immunotherapy developer Scancell has confirmed talks to acquire Nasdaq-listed Neuphoria Therapeutics, in a move that could give the Oxford-based biotech a faster route to US public markets.
EMBL spin-off Epitome launches with €4M
Latest NewsVienna-based Epitome Therapeutics has launched with €4 million in total financing to advance a new epigenome-editing platform designed to precisely control gene expression.